COMPOSITIONS FOR PREVENTING AND TREATING TYPE I ALLERGY

CLAIMS AS FILED

Please cancel Claims 2-6.

Please replace the remaining claims with the following claims:

1. **(Amended)** A composition for preventing or treating type I allergy and diseases associated with type I allergy, comprising kaempferol-3-glucoside (astragalin) in an amount effective to prevent or treat type I allergy and the diseases associated with type I allergy.

7. **(Amended)** A method for preventing or treating type I allergy and diseases associated with type I allergy in a mammal,comprising:

administering to said mammal an effective amount of kaempferol-3-glucoside to prevent or treat type I allergy and the diseases associated with type I allergy.

8. **(Amended)** The method according to claim 7, wherein the diseases associated with type I allergy are atopic diseases.

9. **(Amended)** The method according to claim 8, wherein the diseases associated with type I allergy are selected from the group consisting of: atopic dermatitis, brochial asthma, allergic rhinitis, allergic contact dermatitis, pollinosis, and urticaria.

Please add the following claims:

10. The method according to claim 7 wherein the effective amount is from about 0.025 to about 3 mg per day per kg of body weight.

11. The method of claim 10 wherein the effective amount is from about 0.05 to about 1.5 mg per day per kg of body weight.

12. The method of claim 7 wherein the administration is selected from the group consisting of: orally, intravenously, topically, intramuscularly, intracutaneously, subcutaneously, intraperitoneally, and by aerosolization.

13. The method of claim 12, wherein the administration is orally, admixed with a food product.

14. The method of claim 13, wherein the food product is selected from the group consisting of: juice, soft drinks, teas, powdered soups, jelly, cookies, biscuits, cereal, crackers, candy, breads, noodles, fish paste, chewing gum, ice cream, and chocolate.

15. The method of claim 7 wherein the administration is between one and 4 doses per day.

16. The composition according to claim 1 wherein the effective amount is from about 0.025 to about 3 mg per day per kg of body weight.

17. The composition of claim 1 wherein the effective amount is from about 0.05 to about 1.5 mg per day per kg of body weight.

18. A pharmaceutical composition comprising the composition of claim 1 with a pharmaceutically acceptable carrier, diluent, or excipient.

19. The pharmaceutical composition of claim 18, wherein said carrier, diluent, or excipient is selected from the group consisting of: powders, lotions, ointments, binders, surfactants, moisturizers, fillers, extenders, wetting agents and food products.

20. The pharmaceutical composition of claim 18 further comprising: antiseptics, colerants, preservatives, antioxidants, aromatics, and food products.

21. The composition of claim 1 wherein said kaempferol-3-glucoside is extracted from plants or chemically synthesized.

22. The composition of claim 21, wherein said plants are selected from the group consisting of: persimmon, amachazuru, gymnema, guava, kuko, striped bamboo, jasmine, sugina, dokudami, loquat, sen-cha, and tien-cha.

23. A method for the reduction of serum IgE in a mammal, comprising:

administering an amount of kaempferol-3-glucoside to said mammal sufficient to reduce serum IgE.

IN THE CLAIMS

Please cancel Claims 2-6.

Please replace the remaining claims with the following claims:

1. **(Amended)** A composition for preventing or treating type I allergy and diseases associated with type I allergy, comprising kaempferol-3-glucoside (astragalin) in an amount effective to prevent or treat type I allergy and the ~~diseases associated with type I allergy~~.

7. **(Amended)** A method for preventing or treating type I allergy and diseases associated with type I allergy in a mammal,comprising:

administering to said mammal an effective amount of kaempferol-3-glucoside to prevent or treat type I allergy and the diseases associated with type I allergy.

8. **(Amended)** The method according to claim 7, wherein the diseases associated with type I allergy are atopic diseases.

9. **(Amended)** The method according to claim 8, wherein the diseases associated with type I allergy are selected from the group consisting of: atopic dermatitis, brochial asthma, allergic rhinitis, allergic contact dermatitis, pollinosis, and urticaria.

Please add the following claims:

10. The method according to claim 7 wherein the effective amount is from about 0.025 to about 3 mg per day per kg of body weight.

11. The method of claim 10 wherein the effective amount is from about 0.05 to about 1.5 mg per day per kg of body weight.

12. The method of claim 7 wherein the administration is selected from the group consisting of: orally, intravenously, topically, intramuscularly, intracutaneously, subcutaneously, intraperitoneally, and by aerosolization.

13. The method of claim 12, wherein the administration is orally, admixed with a food product.

14. The method of claim 13, wherein the food product is selected from the group consisting of: juice, soft drinks, teas, powdered soups, jelly, cookies, biscuits, cereal, crackers, candy, breads, noodles, fish paste, chewing gum, ice cream, and chocolate.

15. The method of claim 7 wherein the administration is between one and 4 doses per day.

16. The composition according to claim 1 wherein the effective amount is from about 0.025 to about 3 mg per day per kg of body weight.

17. The composition of claim 1 wherein the effective amount is from about 0.05 to about 1.5 mg per day per kg of body weight.

18. A pharmaceutical composition comprising the composition of claim 1 with a pharmaceutically acceptable carrier, diluent, or excipient.

19. The pharmaceutical composition of claim 18, wherein said carrier, diluent, or excipient is selected from the group consisting of: powders, lotions, ointments, binders, surfactants, moisturizers, fillers, extenders, wetting agents and food products.

20. The pharmaceutical composition of claim 18 further comprising: antiseptics, colerants, preservatives, antioxidants, aromatics, and food products.

21. The composition of claim 1 wherein said kaempferol-3-glucoside is extracted from plants or chemically synthesized.

22. The composition of claim 21, wherein said plants are selected from the group consisting of: persimmon, amachazuru, gymnema, guava, kuko, striped bamboo, jasmine, sugina, dokudami, loquat, sen-cha, and tien-cha.

23. A method for the reduction of serum IgE in a mammal, comprising:

administering an amount of kaempferol-3-glucoside to said mammal sufficient to reduce serum IgE.

REMARKS

The claims and specification have been amended to correct minor deficiencies and inconsistencies. No new matter has been added herewith. Support for amended claim 9 can be found in the Specification, page 5, lines 5-10. Support for claims 12-14 can be found in the Specification, page 10, lines 17 through page 11, line 7. Support for claims 16-17 can be found in the Specification, page 12, lines 1-5. Support for added claims Support for added claims 21 and 22 can be found in the specification on page 5, line 23 through page 6, line 12. Support for Claim 23 can be found on page 5, line 13-16.

The changes made to the claims by the current amendment, including **[deletions]** and additions are shown on an attached sheet entitled **VERSION WITH MARKINGS TO SHOW CHANGES MADE**, which follows the signature page of this Amendment.

Conclusion

Should there be any questions relating to the above-captioned patent application, the Examiner is respectfully requested to contact the undersigned at the telephone number appearing